GW Pharmaceuticals plc (Nasdaq: GWPH) announces positive results of the first randomized, double-blind, placebo-controlled Phase 3 clinical trial of its ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

GW Pharma's (GWPH) Price Target Raised to $152 at Morgan StanleyJune 28, 2016 7:58 AM GW Pharma (GWPH) PT Raised to $138 at Leerink PartnersJune 27, 2016 9:52 AM GW Pharma (GWPH) Epidiolex Data in LGS 'Looks Good' - LeerinkJune 27, 2016 7:42 AM GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results for Epidiolex® (cannabidiol) in the Treatment of Lennox-Gastaut SyndromeJune 27, 2016 7:00 AM